Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 12.23 BATS BZX Real-Time Price As of 12:29pm ET |  -0.25 / -2.00%Today’s Change | 4.13 Today|||52-Week Range 12.50 | +8.23% Year-to-Date |
Latest MACK News | Press Releases
| Strong On High Relative Volume: Merrimack Pharmaceuticals (MACK) Mar 05 / TheStreet.com | Merrimack Pharmaceuticals' (MACK) Loss Narrows in Q4 - Tale of the Tape Feb 26 / Zacks.com |
| Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Feb 27 / Zacks.com | Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Feb 24 / Zacks.com |
Today’s Trading
| Previous close | 12.48 |
| Today’s open | 12.21 |
| Day’s range | 12.15 - 12.48 |
| Volume | 681,762 |
| Average volume (3 months) | 1,699,857 |
| Market cap | $1.3B |
| Dividend yield | -- |
Data as of 12:17pm ET, 03/06/2015
Growth & Valuation
| Earnings growth (last year) | +39.39% |
| Earnings growth (this year) | -27.29% |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | +115.03% |
| P/E ratio | NM |
| Price/Sales | 11.48 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LGNDLigand Pharmaceutica... | +1.10 | +1.60% |
| NLNKNewLink Genetics Cor... | -0.19 | -0.40% |
| ACHNAchillion Pharmaceut... | +0.15 | +1.36% |
| USNAUSANA Health Science... | -0.20 | -0.20% |
Data as of 12:31pm ET, 03/06/2015
Financials
| Next reporting date | May 12, 2015 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $102.8M |
| Annual profit (last year) | -$83.3M |
| Net profit margin | -81.06% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
